Myfembree is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Myovant Sciences, Inc.. The primary component is Relugolix; Estradiol Hemihydrate; Norethindrone Acetate.
| Product ID | 72974-415_4d145097-231a-4d89-ae96-f3e86752bf7c |
| NDC | 72974-415 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Myfembree |
| Generic Name | Relugolix, Estradiol Hemihydrate, And Norethindrone Acetate |
| Dosage Form | Tablet, Film Coated |
| Route of Administration | ORAL |
| Marketing Start Date | 2021-05-26 |
| Marketing Category | NDA / |
| Application Number | NDA214846 |
| Labeler Name | Myovant Sciences, Inc. |
| Substance Name | RELUGOLIX; ESTRADIOL HEMIHYDRATE; NORETHINDRONE ACETATE |
| Active Ingredient Strength | 40 mg/1; mg/1; mg/1 |
| Pharm Classes | Estradiol Congeners [CS],Estrogen [EPC],Estrogen Receptor Agonists [MoA],Progesterone Congeners [CS],Progestin [EPC] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2022-12-31 |
| Marketing Start Date | 2021-05-26 |
| NDC Exclude Flag | N |
| Sample Package? | N |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() MYFEMBREE 90593915 not registered Live/Pending |
Myovant Sciences GmbH 2021-03-22 |
![]() MYFEMBREE 88768680 not registered Live/Pending |
Myovant Sciences GmbH 2020-01-22 |